Eyenovia, EYEN is showing recent insider trading activity. Public SEC records indicate that Grant Stuart M. recently Bought $233,855 worth of shares on 2 days ago. With that said, our editors here at politicsandwallstreet.com, are adding EYEN to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of EYEN that Sold $516.6K worth of shares in the last 3 months, the Insider Confidence level of Eyenovia is trending Down.
Since these insiders have unique insights into what's happening at Eyenovia, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for EYEN:
In addition, TradingView issued a Sell rating for EYEN over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook.
Here is a bit more on Eyenovia, EYEN but please do your own research.
EYEN Summary: Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to EYEN, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of EYEN that Sold $516.6K worth of shares in the last 3 months, the Insider Confidence level of Eyenovia is trending Down.
Since these insiders have unique insights into what's happening at Eyenovia, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for EYEN:
- Grant Stuart M. - Director, Bought $233,855 worth of shares on 1 day ago
- Ellen Strahlman - >10% Owner, Bought $30,900 worth of shares on 2 days ago
- Charles Mather - Director, Sold $13,560 worth of shares on 1 week ago
- Ianchulev Tsontcho - Director, Sold $495,000 worth of shares on 3 weeks ago
In addition, TradingView issued a Sell rating for EYEN over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook.
Here is a bit more on Eyenovia, EYEN but please do your own research.
EYEN Summary: Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York.
- Recent Last Price: $2.59
- Price Change: $0.12, 4.86%
- Yearly Gain: 8.81%
- Market Cap: $93.87M
- P/E Ratio: -3.308
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to EYEN, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
_30_11zon.webp)
